Compliance & Validation — Documented
21 CFR Part 11
eSource and EDC platform built for research sites, capturing structured data at the point of care, with third-party attested 21 CFR Part 11 compliance.
CRIO (Clinical Research IO), founded in 2015 and headquartered in Boston, Massachusetts, provides eSource, EDC, CTMS, and eRegulatory tools designed from the research site's perspective, capturing structured data at the point of collection to build quality into trials upstream. In May 2024 the private equity firm The Riverside Company acquired CRIO through its Riverside Micro-Cap Fund; the company continues to operate under its own brand. Its security page documents third-party attested 21 CFR Part 11 compliance. The platform is site-first by design, so sponsors and CROs should validate sponsor-facing analytics and data-integration depth during evaluation.
64% — Partial coverage. Coverage score — how completely Atlas documents CRIO across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
21 CFR Part 11
cloud
Ask the vendor: What is your pricing model, and what drives total cost of ownership?
Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?
Biotech Startup, Mid-Size Biotech, CRO / CDMO, Clinical Operations, Data Management
Clinical Data Management
Private equity, Founded 2015
Not captured in Atlas data — confirm directly. Excluded from the score above.
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?